Design, synthesis, and evaluation of orally active fibrinogen inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 5, 1997, Pages 521-526

  Tanaka, Akito ^a   Sakai, Hiroyoshi ^a   Ishikawa, Takatoshi ^a   Aoki, Toshiaki ^a   Motoyama, Yukio ^a   Takasugi, Hisashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALINE; 4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALYLTHIOMORPHOLINE 1,1 DIOXIDE; 4 (4 AMIDINOPHENOXY)BYTYRYLASPARTYLVALYLTHIOMORPHOLINE 1,1 DIOXIDE; ANTITHROMBOCYTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DOG; DRUG DESIGN; DRUG STABILITY; DRUG SYNTHESIS; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE FLUID; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALIA; CANIS FAMILIARIS; CAVIA PORCELLUS; SUS SCROFA;

EID: 0031552142     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00055-3     Document Type: Article

References (14)

1. 1. Davies, M. J.; Thomas, A. C. Br. Heart J., 53, 363 (1985).
2. 2. Hamm, C. W.; Bleifield, W.; Kupper, W.; Lorenz, R. L.; Weber, P. C.; Wober, W. J. Am. Coll. Cardiol., 10, 998 (1987).
3. 3. Ruoslahti, E.; Pierschbacher, M. D. Science 1987, 238, 491-497.
4. 4. Samanen, J. Annual Reports in Medicinal Chemistry 1996, 31, 91-100.
5. 5. a) Tanaka, A.; Sakai, H.; Ishikawa, T.; Nakanishi, I.; Ohkubo, M.; Aoki, T.; Motoyama, Y.; Takasugi, H. Bioorg. Med. Chem. Lett. 1996, 6, 1443-1448.
6. b) Tanaka, A; Sakai, H.; Motoyama, Y.; Ishikawa, T.; Takasugi, H.; J .Med. Chem. 1994, 37, 1189-1199.
7. 6. Aoki, T.; Cox, D.; Senzaki, K.; Seki, J.; Tanaka, A.; Takasugi, H.; Motoyama, Y. Thrombosis Research, 81, 439-450 (1996).
8. 5b).
9. 9 (32 mg/kg, data not shown).
10. 9. Storm, D. R., Ann. N. Y. Acad. Sci. 1974, 235, 387.
11. 3CN in 0.1 % TFA aq.; Flow, 118 ml/min; Detection, 254 nm; Retention time, 9.8 min.
12. 5a
13. 3CN in 0.1 % TFAaq.; Flow, 118 ml/min; Detection, 254 nm; Retention time, 9.8 min. Compounds 2b-f, and 3a-f were prepared in a manner similar to that of 2a. The yields of the last reaction of these compounds were shown in Table 3.
14. +).